Navigation Links
Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
Date:10/8/2008

PRINCETON, N.J., Oct. 8 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the Natixis Bleichroeder Hidden Gems Conference being held from October 13-14, 2008 at the Waldorf Astoria in New York City. Michelle Berrey, Pharmasset's Chief Medical Officer, will provide an overview of the company on Monday, October 13, 2008, at 11:30 AM (ET).

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Richard E.T. Smith

Vice President of Investor Relations

richard.smith@pharmasset.com

Office: +1 (609) 613-4181


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
2. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
3. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
4. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
5. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
6. Pharmasset Joins Russell 3000 Index
7. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
8. Pharmasset Selected to Join the NASDAQ Biotechnology Index
9. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
10. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
11. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... Ovation ... infertility as a disease, bringing new hope for prospective parents who are challenged ... meeting to back the World Health Organization’s designation in hopes of changing the ...
(Date:6/22/2017)... ... June 22, 2017 , ... Tunnell Consulting’s ... and life sciences industries, continue to be in demand for their insights and ... be speaking on “The State of Information Governance in the Biopharmaceutical Industry” at ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... the release of Limfinity® version 6.5, a content-packed update to the Limfinity® framework. ... gain a larger and more diverse base of customers among labs and other ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... board of directors has formed a Higher Education Entrepreneurship Advisory Committee to implement ... institution presidents and other high-ranking representatives from 35 higher education institutions across the ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and Touchless), ... published by MarketsandMarkets, the market is expected to be worth USD 18.98 billion ... Continue Reading ... ...      (Logo: ...
(Date:3/22/2017)... March 21, 2017 Vigilant Solutions , ... law enforcement agencies, announced today the appointment of retired ... of public safety business development. Mr. Sheridan ... experience, including a focus on the aviation transportation sector, ... recent position, Mr. Sheridan served as the Aviation Liaison ...
Breaking Biology News(10 mins):